The University of Oxford will launch a study, funded by the British government, for the first worldwide trial .. aimed at establishing the efficacy of administering a mix of vaccines, with a first dose of one serum and a second dose of a different vaccine.
Eight hundred and twenty people over the age of 50 who have not yet been immunized will undergo the trial to receive a first dose of either the Oxford-AstraZeneca or Pfizer-BioNTech vaccine. Some will then receive an alternative vaccine at the second appointment within 12 weeks, while others will receive the same vaccine again.
by Xavier Cuesta – European Correspondent – EuroNews
Short Link :
copied
(Visited 1 times, 1 visits today)